Advertisement

Correction to: Multicenter, Randomized, Controlled Study Comparing Tafluprost/Timolol Fixed Combination with Latanoprost/Timolol Fixed Combination in Primary Open-Angle Glaucoma and Ocular Hypertension

  • Katsuyoshi Suzuki
  • Naomi Otsuka
  • Hiroko Hizaki
  • Masayo Hashimoto
  • Yasuaki Kuwayama
  • On behalf of the Tafluprost/Timolol Versus Latanoprost/Timolol (TTVLT) Study Group
Correction
  • 89 Downloads

Correction to: Adv Ther (2018) 35:796–808  https://doi.org/10.1007/s12325-018-0718-9

In the original publication, the range to derive the P values is incorrectly represented in Tables 2 and 3. The corrected tables are provided below.
Table 2

Mean (± standard deviation) superficial punctate keratopathy scores (range 0–3)

Bold indicates significant values

BL baseline, LAT latanoprost, SPK superficial punctate keratopathy, TAF tafluprost, TIM timolol

aData missing for one patient in the LAT/TIM group

bCalculated using Wilcoxon two-sample test

cCalculated using Wilcoxon one-sample test

Table 3

Mean (± standard deviation) tear break-up times and hyperemia scores (range 0–3)

BL baseline, LAT latanoprost, TAF tafluprost, TBUT tear breakup time, TIM timolol

aData missing for one patient in the LAT/TIM group

bCalculated using t test

cCalculated using Wilcoxon two-sample test

dCalculated using Wilcoxon one-sample test

Copyright information

© Springer Healthcare Ltd., part of Springer Nature 2019

Authors and Affiliations

  • Katsuyoshi Suzuki
    • 1
  • Naomi Otsuka
    • 2
  • Hiroko Hizaki
    • 2
  • Masayo Hashimoto
    • 2
  • Yasuaki Kuwayama
    • 3
  • On behalf of the Tafluprost/Timolol Versus Latanoprost/Timolol (TTVLT) Study Group
  1. 1.Suzuki Eye ClinicYamaguchiJapan
  2. 2.Santen Pharmaceutical Co., Ltd.OsakaJapan
  3. 3.Fukushima Eye ClinicOsakaJapan

Personalised recommendations